Industrial Policy & Trade Monitor· 2666 actions· ✨ 90 recent

The British Business Bank, the UK government's economic development bank, announced an GBP 8 million equity investment into NRG Therapeutics Ltd on 8 September 2025 as part of an oversubscribed GBP 50 million (USD 67 million) Series B financing round. NRG Therapeutics develops small-molecule mitochondrial permeability transition pore (mPTP) inhibitors for neurodegenerative diseases including ALS/MND and Parkinson's. The round was led by SV Health Investors' Dementia Discovery Fund, with participation from M Ventures, Novartis Venture Fund, Criteria Bio Ventures, and existing investors Omega Funds and Brandon Capital; a British Business Bank representative joined NRG's board.

President Trump signed Executive Order 14345 on 4 September 2025, implementing the July 2025 US-Japan trade agreement by setting a 15% baseline ad-valorem tariff on nearly all Japanese goods — raising any Column 1 (MFN) duty rate below 15% up to that floor, including on agricultural lines such as cereals, vegetables, and fruits and nuts. The modification applies retroactively to Japanese products entered for consumption on or after 12:01 a.m. EDT, 7 August 2025, and supersedes the higher 24% country-specific reciprocal rate Japan faced under the April 2025 "Liberation Day" schedule. Aerospace products are exempted entirely, autos/auto parts receive the same 15% treatment (down from a separate 25% Section 232 rate), and Japan committed to $550bn in US investment and $8bn/year in additional US agricultural purchases (rice, corn, soybeans, fertilizer, bioethanol) as consideration.

On 3 September 2025, the U.S. Treasury's Office of Foreign Assets Control (OFAC) designated Guangzhou Tengyue Chemical Co., Ltd., a China-based chemical manufacturer, along with two of its representatives, Huang Xiaojun and Huang Zhanpeng, pursuant to Executive Order 14059 for materially contributing to the international proliferation of illicit drugs. The company was found to have manufactured and sold synthetic opioids — including nitazenes — and analgesic cutting agents such as xylazine and medetomidine to U.S. buyers. The designation blocks all U.S.-person property and transactions involving the three designated persons and any entity 50%-or-more owned by them; the FBI simultaneously announced a related federal indictment against Guangzhou Tengyue, the two individuals, and roughly 22 other China-based individuals and businesses for conspiracy to commit drug trafficking.

On 29 August 2025 the Pinggu District (Beijing) Science, Technology and Economic Informatization Bureau issued "Several Measures to Promote the High-Quality Development of High-End Manufacturing in Pinggu District" (平谷区促进高端制造业高质量发展若干措施), published to the district government portal on 25 September 2025 with a two-year validity period. The scheme offers manufacturers registered and operating in Pinggu a stack of output-growth, R&D, smart-factory, green-transformation, pharma/medical- device, auto-parts-supply-chain, and synthetic-biology subsidies, with per-recipient caps ranging from RMB 200,000 up to RMB 10 million for qualifying pharmaceutical/medical-device innovators.

South Korea's National Assembly passed an amendment to the Korea Development Bank (KDB) Act on 2025-08-27 (428th session, 3rd plenary sitting, 164-1 with 164 votes in favour of 165 cast), raising KDB's statutory capital ceiling from KRW 30 trillion to KRW 45 trillion and creating a new "Advanced Strategic Industry Fund" inside KDB. The fund is capitalised at KRW 50 trillion or more over five years via low-rate government-guaranteed bonds and is earmarked for the ten officially designated advanced strategic industries (AI, semiconductors, bio/vaccines, defense, robotics, hydrogen, secondary batteries, displays, future mobility) via cheap loans and equity investment. KDB intends to use the fund as seed capital for a wider "National Growth Fund" that blends in private and pension capital to reach KRW 100 trillion+ in total strategic-industry financing over five years.

Act L of 2025 (2025. évi L. törvény) is the Hungarian National Assembly statute that elevates a set of war-emergency government decrees — including the foreign-investment screening regime previously embedded in Government Decree 561/2022 — to permanent statutory level. Promulgated in Magyar Közlöny and entered into force on 19 August 2025, the Act preserves Hungary's "Second Regime" of FDI screening operating in parallel with the General Regime (which implements EU Reg 2019/452 since 2019). The Second Regime applies to a broad set of strategic sectors — energy, transport, communications, telecoms, pharmaceuticals, food processing, defence, financial services and healthcare — and requires approval from the Minister of National Economy for qualifying acquisitions (direct or indirect majority, ≥5% interest, ≥3% in listed companies, or ownership/operation of strategic infrastructure) where transaction value reaches HUF 350 million (~EUR 890,000). Notification is due within 10 days of signing; the MoE originally had 30 business days (extendable +15 calendar days). The Act also entrenches the Hungarian state right of first refusal on photovoltaic generation companies (NACE 35.11'08, excluding sub-50 kVA household installations), exercised through MNV Zrt. The Special Regime is structurally distinct from the General Regime and represents Hungary's peer to the German AWG §§55-62, French Décret 2014-479, Dutch Wet Vifo, and Italian Golden Power. Amended by Act XCIII of 2025 (in force 17 December 2025), which extended the MoE screening deadline to 45 business days and excluded bank-financing security arrangements from notification.

The Hainan Provincial People's Government General Office issued "Several Policy Measures of Hainan Province for Further Supporting High-Quality Development of the Biopharmaceutical Industry" (Qiong Fu Ban [2025] No. 38) on 2025-08-14, effective 2025-09-13 for a three-year term. The package disburses provincial subsidies across the full biopharma value chain — R&D-stage grants, national centralized-procurement awards, international-certification bonuses, platform-investment reimbursement, and traditional-Chinese-medicine insurance-listing awards — leveraging Hainan Free Trade Port status to build a regional biomedical industry cluster.

On 13 August 2025 President Trump signed an Executive Order ("Ensuring American Pharmaceutical Supply Chain Resilience by Filling the Strategic Active Pharmaceutical Ingredients Reserve", Federal Register Doc. 2025-15823, published 19 August 2025) directing the HHS Assistant Secretary for Preparedness and Response (ASPR) to refill and operationalise the Strategic Active Pharmaceutical Ingredients Reserve (SAPIR). Within 30 days, ASPR must compile an initial list of 26 essential drugs, account for available funding, and acquire and maintain a six-month supply of the corresponding APIs. Within 90 days, ASPR must deliver an expanded list of up to 86 essential medicines and medical countermeasures plus a plan to source those APIs from domestic manufacturers, and within 120 days (subject to appropriations) ready the existing SAPIR repository and submit a proposal and cost estimate for opening a second repository. The order prioritises domestically manufactured APIs in federal procurement and reserve build-out and directs interagency coordination across HHS/ASPR, FDA, DoD (Industrial Base Fund / Defense Production Act Title III), and the Department of Commerce.

Wisconsin Governor Tony Evers and the Wisconsin Economic Development Corporation (WEDC) announced on 5 August 2025 a package of up to $100 million in performance-based Enterprise Zone state tax credits to support Eli Lilly and Company's $4 billion expansion of its parenteral (injectable) drug manufacturing site in Bristol, Kenosha County. The credits are split between up to $18 million for job creation and up to $82 million for capital investment, contingent on Lilly creating at least 700 jobs and making at least $2.2 billion in qualifying capital investment, with the allocation period running through 2036.

The Cabinet of Ministers of the Republic of Armenia, chaired by Deputy Prime Minister Mher Grigoryan, approved the 2025-2030 Strategic Plan for Promoting Exports of the Republic of Armenia and its accompanying Action Plan on 31 July 2025. The Strategy targets a 1.7-fold increase in total Armenian exports to USD 16.9 billion by 2030 (USD 10.3 billion services + USD 6.6 billion goods), with an implementation envelope of approximately AMD 98 billion (~USD 250 million). It designates critical minerals (copper-molybdenum concentrates, gold, antimony, emerging rare-earth-element zones), IT and tech services, agri-processing, and green-transition equipment as priority export categories, and operationalises Armenia's ongoing reorientation of export geography away from Russia/EAEU toward EU, US, Gulf, and Asian markets.

On 27 July 2025, President Trump and European Commission President Ursula von der Leyen reached political agreement at Turnberry, Scotland, on a Framework Agreement on Reciprocal, Fair and Balanced Trade. The framework was formalised in a Joint Statement published on 21 August 2025 by the White House and DG TRADE. The deal establishes a 15% all-inclusive (MFN + Section 232) US tariff ceiling on the vast majority of EU originating goods — including autos, pharmaceuticals, semiconductors, lumber, and chemicals — replacing the threatened 20-30% reciprocal tariff trajectory under EO 14257 (April 2025). Steel and aluminium are excluded from the 15% ceiling and remain at the 50% Section 232 rate pending negotiation of a quota solution. In return, the EU commits to: (i) eliminate tariffs on all US industrial goods, (ii) preferential market access for a wide range of US agricultural and seafood products, (iii) suspension of its rebalancing countermeasures under Reg 2025/778 (suspension effective 7 August 2025), (iv) expected energy offtake of $750bn (LNG, oil, nuclear) through 2028, (v) at least $40bn in US AI chip purchases, and (vi) facilitation of $600bn in additional EU corporate investment into the US through 2028. Effective from 1 September 2025, the US applies MFN-only treatment (no 15% top-up) to: aircraft and parts, generic pharmaceuticals and ingredients, chemical precursors, cork, and certain unavailable natural resources. The framework is not legally binding but anchors the bilateral architecture; it is the largest-economy ART-programme deal alongside US-UK, US-Japan, US-Korea, US-Taiwan, and US-Indonesia.

The National Reconstruction Fund Corporation (NRFC), Australia's AUD 15 billion sovereign industrial-financing vehicle, committed AUD 150 million to Brandon Capital's Brandon BioCatalyst 6 (BB6) fund, announced 24 July 2025. Brandon Capital — Australasia's largest life-sciences venture capital manager, with over AUD 1 billion under management — closed BB6 at AUD 439 million total, with the NRFC contribution the largest single commitment. The fund backs early- and late-stage Australian medical-science companies developing therapeutics, medical devices and vaccines, with roughly one-third earmarked for early-stage ventures and the remainder for late-stage clinical development and commercialisation. NRFC frames the deal as building sovereign medical-manufacturing and R&D capability and keeping Australian biotech IP and jobs onshore rather than migrating offshore for follow-on capital.

The UK Department of Health and Social Care added five tuberculosis-treatment antimicrobials to its list of medicines that cannot be parallel-exported from the UK or hoarded, effective 17 July 2025: Rifampicin capsules/powder and solvent for infusion (all strengths), Pyrazinamide 500mg tablets, Rifampicin + Isoniazid 300mg/150mg tablets, Rifampicin + Isoniazid + Pyrazinamide 120mg/50mg/300mg tablets, and Voractiv tablets (all strengths). The restriction is issued under regulation 43(2) of the Human Medicines Regulations 2012; breach constitutes a wholesale dealer licence violation enforceable by the MHRA with licence suspension.

The Polish Sejm passed the Act of 9 July 2025 amending the Act of 24 July 2015 on the Control of Certain Investments, signed by the President on 21 July 2025 and effective 24 July 2025. The amendment removes the time-limited "Specialised Rules" tier (introduced in 2020 under the Anti-COVID Shield) and makes Poland's FDI screening regime permanent. Review competence is transferred from the President of UOKiK (the competition authority) to the minister responsible for economic affairs (currently the Minister of Finance and Economy), and a new trigger covering "an international situation distorting the market or competition" is added alongside the existing public-order, security and health grounds.

The European Investment Bank signed a EUR 150 million loan agreement with Italian pharmaceutical group Alfasigma SpA on 8 July 2025 to finance the company's 2025-2027 research and development programme in rare diseases and specialty care (gastroenterology/hepatology, vascular medicine, rheumatology). The EIB framed the operation as part of its agenda to bolster competitiveness and innovation in the European healthcare sector. Global Trade Alert logged the announcement and implementation date as 27 June 2025 (state-act 92597); the EIB's own press release places the signing on 8 July 2025.

France's Ministry of Agriculture, acting through FranceAgriMer, opened a EUR 45 million call for projects on 30 June 2025 to fund research and development of alternatives to chemical crop protection products (phytopharmaceuticals). The call — part of the PARSADA strategic plan launched in spring 2023 to anticipate a potential EU-level withdrawal of active substances — funds 3-to-5 year projects at 40-100% of eligible costs, capped at EUR 7.5 million per project, across eight agricultural sectors. Applications are accepted on a rolling basis through 31 December 2026.

Government Decree 163/2025 (VI. 23.) amends the emergency-era Decree 561/2022 (XII. 23.) on economic-protection deviations, making two operative changes to Hungary's FDI screening regime: it extends the review period from 30 to up to 135 working days (45-day base plus three 30-workday extensions) and introduces a state pre-emption right, exercisable within 90 calendar days of a prohibition decision, allowing MNV Zrt. (Hungarian National Asset Management Company) or a designated entity to acquire the blocked target on the same terms as the original parties. The decree applies retroactively to all notification procedures pending at the time of entry into force (24 June 2025) and expands the screening scope from a solar-sector focus to broad strategic sectors. It served as an interim bridge — in force from 24 June to 18 August 2025 — until superseded by the permanent statutory codification in Act L of 2025.

On 2025-06-02 Mexico published a presidential decree ("DECRETO por el que se fomenta la inversión en territorio nacional, para fortalecer el desarrollo de la industria farmacéutica y la producción de insumos para la salud; así como el desarrollo de investigación científica nacional") in the Diario Oficial de la Federación, effective 2025-06-03. Starting with fiscal-year 2026 consolidated federal purchases of medicines, health inputs and medical devices (for 2027 delivery), the Secretaría de Salud will apply a points-and-percentage evaluation scheme that favors bidders holding productive investment or infrastructure (plants, laboratories, warehouses) in Mexico, or that conduct scientific research domestically. A tri-ministry Promotion Committee (Health, Economy, and the Anticorruption/Public Function ministry) will vet investment commitments, and the decree directs the Secretaría de Salud to issue implementing guidelines within 90 calendar days of publication.

On 28 May 2025, Brazilian President Lula launched "Chamada Nordeste" in Salgueiro (Pernambuco) — a BRL 10 billion (~USD 1.8bn) public call for structuring investment projects in the nine Northeast states, run jointly by BNDES, Banco do Brasil, Caixa Econômica Federal, Banco do Nordeste (BNB) and Finep, with technical support from Sudene and the Northeast Consortium. It is the largest project call ever run for the region and sits under the federal Nova Indústria Brasil (NIB) industrial-policy umbrella. Eligible business plans (minimum BRL 10 million) cover storage/renewable energy, bioeconomy with a pharmaceuticals focus, green hydrogen, green data centers and the automotive/agricultural-machinery sector, financed via a combination of credit lines, non-reimbursable economic subsidies and equity participation; the proposal deadline was 15 September 2025. Demand vastly exceeded supply: the call drew 245 proposals totalling roughly BRL 127.8 billion — nearly 13 times the initial BRL 10bn envelope — before BNDES approved 189 projects worth BRL 113 billion in follow-on selection rounds.

Japan's National Diet passed a partial amendment to the Pharmaceutical and Medical Device Act (PMD Act / 薬機法) on May 14, 2025, promulgated as Law No. 37 of 2025 on May 21. The amendment requires every Marketing Authorization Holder (MAH) to designate a Supply System Manager responsible for reporting supply disruptions to MHLW, and grants MHLW authority to order replacement of key quality personnel when systemic deficiencies are found. It also reforms GMP oversight to a risk-based inspection model and expands the conditional-approval pathway for rare disease and paediatric drugs. Enforcement is staggered across three tranches: November 2025, May 2026, and final full implementation by May 2027.

The UK Department for Science, Innovation and Technology signed a grant agreement with BioNTech UK Ltd. providing up to GBP 129 million in government support over 10 years, underpinning BioNTech's planned GBP 1 billion (USD 1.3 billion) investment in UK research and development over the same period. The funding backs two new R&D hubs: a life-sciences research centre in Cambridge (genomics, oncology, structural biology, regenerative medicine) and an AI hub co-located with BioNTech's planned UK headquarters in London, run by its InstaDeep subsidiary. The government frames the deal as one of the largest single-company investments in UK life-sciences history and part of the Oxford-Cambridge Growth Corridor and Plan for Change industrial strategy.

President Trump signed Executive Order 14273, "Delivering Most- Favored-Nation Prescription Drug Pricing to American Patients", on 12 May 2025. The EO directs HHS, USTR, and Commerce to pursue mechanisms (negotiation targets, importation pathways, and trade-policy levers) to bring the prices Americans pay for innovative prescription drugs into alignment with the *lowest* prices paid by other comparably-developed nations — the "most-favored-nation" (MFN) benchmark. Unlike the Biden-era Inflation Reduction Act drug-price-negotiation provisions (which apply to a handful of Medicare Part D drugs), the EO applies pressure across the broader pharmaceutical pricing surface. As of April 2026, 17 major pharmaceutical manufacturers (incl. Eli Lilly, Pfizer, Bristol-Myers Squibb, AbbVie, Merck, AstraZeneca, Regeneron) have signed bilateral agreements bringing US drug prices toward the international- benchmark level for selected medications.

On 8 May 2025, President Trump and UK Prime Minister Starmer announced the General Terms of the US-UK Economic Prosperity Deal (EPD), the first bilateral framework arrangement of the second Trump administration and the template instrument for subsequent US bilateral framework deals (US-Japan, US-Indonesia, US-Argentina, US-Korea, US-EU). The framework was implemented on 23 June 2025 via Executive Order 14309 (Federal Register doc 2025-11473). Key US concessions: a 100,000-vehicle annual TRQ for UK autos at a 10% combined rate (7.5% + 2.5% MFN, vs. 27.5% Section 232 default); aerospace tariff reduction back to MFN rates; authority delegated to Commerce/USTR to establish UK-only TRQs for steel and aluminum (in lieu of the 50% Section 232 global rate). Key UK concessions: 13,000 mt duty-free beef quota (with 20% tariff removal on the existing 1,000 mt WTO quota); 1.4 billion litre duty-free ethanol quota; commitment to negotiate non-tariff barrier reductions and supply-chain security alignment. The 10% IEEPA "reciprocal" baseline tariff on most other UK goods is preserved by the EPD.

Bpifrance, France's state-owned public investment bank, took a 1.8% equity stake with board representation in Opella — the Sanofi-spun-off consumer healthcare unit that makes Doliprane (paracetamol) and other OTC brands — as part of the closing of Sanofi's sale of a 50% controlling stake to US private equity firm Clayton, Dubilier & Rice (CD&R). Sanofi retains 48.2%. The stake was widely read domestically as a state sovereignty guarantee attached to a politically contentious foreign takeover of a company regarded as critical to French medicine supply security.

On 11 March 2025 the European Commission published its proposal for a Critical Medicines Act (CMA), pillar of the broader EU pharmaceutical-resilience agenda alongside the EU Critical Raw Materials Act (filed: 2024-05-23-eu-crma-entry-into-force) and the IRA-style industrial-policy stack. The proposal targets supply security of an EU "Union List" of critical medicines (antibiotics, anti-thrombotics, oncology, cardiovascular, insulin, painkillers) by introducing four mechanisms: (1) Strategic Project status with expedited funding access for critical-medicine manufacturing or active-substance production; (2) public-procurement preferences favouring resilient supply chains and — in defined cases — EU-based production; (3) collaborative cross-Member-State procurement to address fragmented small markets; (4) state-aid framework guidance + international-partnership diversification to reduce single-country (often China-routed) API dependency.

On 9 January 2025, Prime Minister and Minister of Foreign Affairs HE Sheikh Mohammed bin Abdulrahman bin Jassim Al Thani unveiled the Qatar National Manufacturing Strategy 2024–2030 alongside the Ministry of Commerce and Industry (MoCI) sectoral strategy at the Qatar National Convention Centre. The manufacturing strategy targets raising sectoral value-add to QAR 70.5bn (~USD 19.4bn), lifting non-hydrocarbon industrial exports above QAR 49bn (~USD 13.5bn), attracting annual industrial investment of QAR 2.75bn (~USD 755m), and placing Qatar among the world's top 40 economies in the UNIDO Competitiveness Industrial Performance index by 2030. It is built on four transformative pillars: shift to smart and green manufacturing, R&D-led productivity uplift, alignment of education and training with industrial demand, and expansion of Qatari workforce participation (Qatarisation), delivered through 15 strategic initiatives and 60 projects.

Vietnam's 15th National Assembly passed Law 44/2024/QH15 on 21 November 2024, comprehensively amending the 2016 Law on Pharmacy. The law liberalises foreign-invested enterprise (FIE) rights — permitting FIEs to wholesale self-imported drugs and APIs and to operate pharmacy chains for the first time — while introducing a special investment-incentive tier for pharma projects capitalised at ≥ VND 3,000 billion (≈ USD 120m) with ≥ VND 1,000 billion disbursed within three years. Online retail of non-prescription drugs is formally legalised as a distinct regulated business activity. Most provisions take effect 1 July 2025; selected marketing-authorisation renewal procedures took effect 1 January 2025. Implementing Decree 163/2025/ND-CP, effective 1 July 2025, provides detailed operational guidance.

Bahrain's Ministry of Industry and Commerce issued Decision No. 53 of 2024, amending the conditions governing foreign ownership in commercial activities, effective 18 October 2024. The reform permits 100% foreign ownership of commercial enterprises — including wholesale and retail trade and authorized distribution — without a mandatory Bahraini local partner, where the foreign company operates in at least 10 countries or generates annual revenue above EUR 750 million. It simultaneously reduces the minimum capital requirement for foreign-owned companies in Bahrain by 95%, from BHD 2,000,000 (~EUR 5m) to BHD 100,000 (~EUR 240,000), materially expanding the addressable foreign-investor pool to mid-market commercial enterprises.

The U.S. Department of the Treasury's Office of Foreign Assets Control (OFAC) issued a final rule amending three sanctions programs. The rule adds a new general license at 31 CFR § 525.512 to the Burma Sanctions Regulations authorizing the provision of agricultural commodities, medicine, medical devices, replacement parts and components for medical devices, and software updates for medical devices to individuals whose property and interests in property are blocked. It also updates the authorities section of the Burma Sanctions Regulations to reflect recent legislation, replaces "the Office of Foreign Assets Control" / "the Director of the Office of Foreign Assets Control" with the acronym "OFAC" in three sections of the Sudan Stabilization Sanctions Regulations, and corrects a cross-reference in the Ukraine-/Russia- Related Sanctions Regulations. The rule is effective on publication.

On 21 March 2024, President William Ruto formally launched Kenya's Fourth Medium Term Plan 2023-2027 (MTP IV) at State House Nairobi, the final five-year implementation plan under the Kenya Vision 2030 blueprint. MTP IV is the operational vehicle for the Bottom-Up Economic Transformation Agenda (BETA), the Ruto administration's foundational industrial-policy and value-chain framework. The plan organises Kenya's industrial-policy push around five core BETA pillars and nine value chains: agro-processing (incl. edible-oil crops, leather, dairy, tea), textiles and apparel, housing and settlement, healthcare and pharmaceuticals, digital superhighway and creative economy, manufacturing (incl. automotive and EV motorcycle and vehicle assembly), MSME and cooperative sector strengthening, and blue-economy/natural-resource value addition. Implementation is anchored in County Aggregation and Industrial Parks (CAIPs) across all 47 counties and in the County Integrated Development Plans (CIDPs). MTP IV is the umbrella framework shaping Kenya's domestic industrial-incentive architecture, foreign-investment priorities, and AfCFTA positioning over 2023-2027. Subsequent sectoral instruments — including the Mining Royalty Collection and Management Regulations 2024 — operate within this policy perimeter. This is the first KE foundational industrial-policy filing in the register.

Belgium's Loi du 29 février 2024 (published in the Moniteur Belge on 27 May 2024, entering into force 1 June 2026) establishes the first comprehensive federal authorisation and traceability regime for pharmaceutical raw materials used by pharmacists in extemporaneous and magistral preparations. Manufacturers, importers, and distributors of covered materials must obtain AFMPS authorisation and comply with Good Manufacturing Practice and Good Distribution Practice standards; pharmacists may only source materials from authorised actors. The statute was enacted during Belgium's EU Council Presidency (H1 2024) and directly parallels the EU Critical Medicines Alliance architecture launched in Leuven on 24 April 2024, positioning Belgium as the first EU member state to operationalise a national supply-chain control layer for pharmaceutical compounding raw materials ahead of the forthcoming EU Critical Medicines Act.

Three-year export-promotion policy issued by the Bangladesh Ministry of Commerce on 25 February 2024 covering FY2024-25 through FY2026-27. Sets a $110bn merchandise+services export target by FY2026-27 (vs. ~$56bn FY2023-24 base), restructures the cash-incentive regime, and designates "highest priority" and "special development" sectors including ready-made garments, leather, jute, ICT, pharmaceuticals, agro-processing, light engineering, and plastics. Explicitly designed as the transition framework for navigating Bangladesh's LDC graduation (effective 24 November 2026), at which point the country will lose EU Everything-But-Arms duty-free access and face an estimated 10% average MFN tariff on EU exports.

Switzerland's Federal Council promulgated the Verordnung über die Mindestbesteuerung grosser Unternehmensgruppen (Mindestbesteuerungsverordnung, MindStV; French: OIMin), SR 642.161, AS 2023 841, on 22 December 2023, with effect from 1 January 2024. The ordinance enacts a 15% Qualified Domestic Minimum Top-up Tax (QDMTT — Ergänzungssteuer) on Swiss constituent entities of MNE groups with consolidated annual revenue ≥ EUR 750 million, enacted under the temporary constitutional authority granted by Swiss voters in a popular referendum on 18 June 2023 (78.5% yes, Art. 129a BV). The Income Inclusion Rule (IIR) and Undertaxed Profits Rule (UTPR) were deliberately deferred to subsequent ordinance amendments, targeting FY 2025 phasing. The Swiss Federal Tax Administration (ESTV / AFC) is the administering authority; first QDMTT returns and GloBE Information Returns due 30 June 2026.

Ireland's Screening of Third Country Transactions Act 2023 (Act No. 28 of 2023), signed into law on 31 October 2023 and commenced on 6 January 2025 via S.I. No. 651 of 2024, establishes Ireland's first-ever mandatory inbound FDI screening regime. The Act empowers the Minister for Enterprise, Tourism and Employment to assess, condition, or prohibit transactions by third-country investors (non-EU/EEA/Switzerland) exceeding a EUR 2 million cumulative threshold in targets operating across critical infrastructure, critical technologies, dual-use items, supply of critical inputs, sensitive personal data, and media freedom. A 90-day standstill period applies during Ministerial determination, with criminal sanctions and transaction-voiding powers available for non-compliance.

Malaysia's New Industrial Master Plan 2030 (NIMP 2030) is the fourth-edition national industrial master plan launched on 1 September 2023 by Prime Minister Anwar Ibrahim under the Ministry of Investment, Trade and Industry (MITI). Spanning seven years to 2030, NIMP 2030 adopts a mission-based approach with 4 missions, 21 strategies and 62 action plans, mobilising an RM95bn investment envelope (predominantly private-sector capital channelled through private equity and the capital markets). The plan targets a step-change in manufacturing-sector economic complexity, deeper local-industry linkages and expanded participation in global supply chains, with explicit numerical targets for the manufacturing sector's GDP contribution and annual growth by 2030.

Framework Law n° 03-22 forming Morocco's Investment Charter, promulgated by Dahir n° 1-22-76 of 14 joumada I 1444 (9 December 2022) and published in Bulletin Officiel n° 7152 (12 December 2022), replaces the 1995 Investment Charter (Law 18-95) — the first major overhaul of Morocco's horizontal investment-incentive regime in nearly 30 years. Operationalised by Decree n° 2.23.1 (Government Council 26 January 2023, BO publication February 2023), the regime layers a "main" support mechanism (CAPEX subsidies up to 30% combining sector-priority, regional/territorial, gender, sustainable and value-chain bonuses) and a "specific" mechanism for strategic projects ≥ MAD 2bn (~USD 200m) covering EV/batteries, semiconductors, green hydrogen, defence and pharmaceuticals — providing the legal foundation for Morocco's emergence as Africa's leading EV-battery and automotive industrial hub.

Council Regulation (EU) 2022/2372, adopted 24 October 2022, establishes a binding framework empowering HERA (Health Emergency Preparedness and Response Authority) to activate emergency supply measures for crisis-relevant medical countermeasures — vaccines, therapeutics, PPE, medical devices, and in-vitro diagnostics — when a public health emergency at Union level is declared under Regulation (EU) 2022/2371. Emergency-mode powers include joint procurement on behalf of Member States, mandatory information requests to manufacturers on stockpiles and production capacity, accelerated R&D funding under the Emergency Research and Innovation Plan, and Union-level stockpile authority. This is the foundational binding instrument for the EU's post-COVID medical supply-chain resilience architecture; it is referenced by every subsequent EU pharma-resilience initiative including the Critical Medicines Act proposal (2025) and the 2025 MCM Strategy.

On 18 October 2022, Crown Prince Mohammed bin Salman launched Saudi Arabia's National Industrial Strategy (NIS) under the Vision 2030 umbrella, with delivery led by the Ministry of Industry and Mineral Resources (MIM). The strategy prioritises 118 segments within 12 industrial sub-sectors (including downstream chemicals, automotive, aerospace, machinery, and metals), identifies more than 800 investment opportunities estimated at ~USD 266bn, and sets binding 2030/2035 targets: triple manufacturing GDP by 2030, raise industrial exports to SAR 557bn (~USD 148bn), bring cumulative additional investment to SAR 1.3 trillion, and grow factories from ~10,000 to ~36,000 by 2035. NIS sits alongside the National Industrial Development and Logistics Program (NIDLP, 2019) and the Public Investment Fund's strategic-sector mandates as the third leg of the Kingdom's non-oil-economy build-out.

Bangladesh's Cabinet approved the National Industrial Policy 2022 on 11 August 2022, replacing the National Industrial Policy 2016 as the country's foundational umbrella industrial-policy statute; the Ministry of Industries gazetted it on 29 September 2022. The policy sets a target to raise industry's share of GDP to 40% by 2027 and introduces a sector taxonomy covering export-diversification, special-development (electronics, automotive assembly, semiconductors, renewable energy, defence-electronics), priority, reserved, and controlled categories. CMSMEs (Cottage, Micro, Small, and Medium Enterprises) are designated the "main driving force of industrialisation," with sector-specific concessional finance, tax holidays, and cluster-development frameworks, alongside FDI incentives including Bangladeshi citizenship for investors committing USD 1 million. The policy for the first time formally incorporates Bangladesh's informal sector within a national industrial-policy framework, mandating a National Informal Sector Database and a 2022–2027 implementation action plan.

Loi n° 22-18 du 24 juillet 2022 relative à l'investissement (Journal Officiel de la République Algérienne n° 50 du 28 juillet 2022) is Algeria's first comprehensive investment-code overhaul since Ordonnance 01-03 du 20 août 2001 and its 2016 Loi 16-09 amendment. The law replaces the legacy framework, codifies a liberalised FDI regime — retaining 51% Algerian-equity floors only for strategic sectors (hydrocarbons extraction, mining extraction, military/security) — creates the Agence Algérienne de Promotion de l'Investissement (AAPI) as the new single-window FDI-promotion agency and the Conseil National de l'Investissement (CNI) chaired by the Premier Ministre, and defines three investment regimes: Régime des Secteurs, Régime des Zones (Sud + Hauts-Plateaux territorial incentives), and the Régime Structurant for large-scale strategic projects ≥ DZD 2bn (~USD 15M) that attract negotiated multi-pillar fiscal, customs, parafiscal, and social-contribution incentive packages. Eight implementing décrets exécutifs n° 22-296 through 22-303 were published in JORADP n° 60 du 18 septembre 2022, operationalising governance, incentive matrices, the digital Registre National des Investissements, and dispute-resolution architecture.

Russian Government Resolution No. 506 of 29 March 2022, signed by Prime Minister Mikhail Mishustin and effective 30 March 2022, authorises the Ministry of Industry and Trade (Minpromtorg) to designate categories of goods exempt from articles 1252(4), 1359(6) and 1487 of the Russian Civil Code on national/regional exhaustion of trademark and other intellectual- property rights. Followed by Minpromtorg Order No. 1532 of 19 April 2022 publishing an initial list of 55 goods categories and named brands — including pharmaceuticals, electronics, automotive parts, mineral fuels, industrial chemicals, paper, textiles, base metals, and consumer goods — for which parallel (grey-market) imports without IP-holder consent are legalised. Designed as a sanctions-circumvention and supply-substitution instrument after the Western corporate exodus of March 2022; extended annually and most recently re-authorised through 31 December 2026.

The Bureau of Industry and Security (BIS) amended the Export Administration Regulations (EAR) on 8 February 2022 to add 33 persons — all based in China — to the Unverified List (UVL) under EAR §744.15(c), on the basis that BIS could not satisfactorily complete end-use checks for these entities for reasons outside US Government control. Placement on the UVL bars exporters from using any EAR license exception when shipping controlled items to listed parties and requires exporters to obtain a certified UVL Statement from the entity or secure a BIS export licence. Sectors represented include semiconductor manufacturing equipment, optoelectronics, UAVs, specialty chemicals, and biotechnology.

On 22 March 2021, UAE Vice President and Prime Minister Sheikh Mohammed bin Rashid Al Maktoum launched Operation 300bn at Qasr Al Watan in Abu Dhabi — a 10-year national industrial strategy delivered by the newly created Ministry of Industry and Advanced Technology (MoIAT, established July 2020). The strategy targets raising the industrial sector's annual GDP contribution from AED 133bn (~USD 36bn) to AED 300bn (~USD 82bn) by 2031, lifting R&D spend from AED 21bn to AED 57bn (1.3% → 2% of GDP), and supporting more than 13,500 industrial SMEs through an AED 30bn (~USD 8.2bn) Emirates Development Bank (EDB) financing portfolio. Eleven priority sub-sectors are organised into three baskets: Stimulating Growth (food/beverage, pharmaceuticals, electrical equipment), Advanced Manufacturing (petrochemicals, rubber/plastics, machinery), and Industries of the Future (hydrogen, medical technology, space technology).

The Bureau of Industry and Security (BIS) amended the Chemical Weapons Convention Regulations (CWCR, 15 CFR Part 710) and Export Administration Regulations (EAR, 15 CFR Parts 712 and 745) to implement two OPCW Conference of States Parties decisions (C-24/DEC.4 and C-24/DEC.5) from November 2019. The rule adds four chemical families — two families of alkyl phosphonamidic fluorides, O-alkyl phosphoramidofluoridates, and quaternary/bisquaternary carbamates — to CWC Schedule 1(A), effective immediately upon publication. The rule also clarifies the definition of "production" in 15 CFR § 710.1 to include intermediates, by-products, and waste products generated within a defined manufacturing sequence.

The Department of Pharmaceuticals notified the Production Linked Incentive (PLI) Scheme for Promotion of Domestic Manufacturing of Critical Key Starting Materials (KSMs), Drug Intermediates (DIs) and Active Pharmaceutical Ingredients (APIs) on 21 July 2020 via Gazette Notification, with an outlay of Rs 6,940 crore (~USD 920m) over FY 2020-21 to FY 2027-28. The scheme covers 41 identified critical bulk-drug products across four target segments — fermentation-based (Key Fermentation; Niche Fermentation) and chemical synthesis-based (Key Chemical Synthesis; Niche Chemical Synthesis) — paying 20% incentive on incremental sales for fermentation-based products (years 1-4) tapering to 15% (year 5) and 5% (year 6), and a flat 20% over 5 years for chemically-synthesised products. The stated objective is to reduce India's ~70% bulk-drug import dependence on China by establishing greenfield domestic manufacturing capacity with at least 90% domestic value addition for fermentation products and 70% for chemical-synthesis products.

The Trade Expansion Act of 1962 (Pub. L. 87-794, 76 Stat. 872), signed into law by President Kennedy on 11 October 1962 and codified at 19 U.S.C. §§ 1801–1991, is the foundational US statute granting the executive branch broad authority to negotiate tariff reductions and, critically via Section 232 (19 U.S.C. § 1862), to adjust imports of any article found by the Secretary of Commerce to threaten to impair national security. Section 232 empowers the President — on receipt of a Commerce Department affirmative national-security finding — to impose tariffs, quantitative restrictions, or other import-adjustment measures without congressional approval or WTO-required safeguard procedures. From 1962 to the Trump Administration's 2018–2026 wave of Section 232 Proclamations, the authority was invoked primarily for petroleum and machine-tool imports; since 2018 it has become the legal vehicle for national-security tariffs on steel, aluminum, automobiles, copper, timber, critical minerals, semiconductors, and pharmaceuticals, with 19+ IPTM-filed implementing instruments citing Pub. L. 87-794 / 19 U.S.C. § 1862 as their statutory parent.

The Defense Production Act of 1950 (Pub. L. 81-774, 64 Stat. 798, codified at 50 U.S.C. §§4501–4568) is the foundational US statute governing wartime and emergency industrial mobilization. Signed by President Truman on 8 September 1950 during the Korean War, the Act empowers the President to compel industrial priority-rated ordering (Title I / DPAS), authorize direct investment in domestic production capacity for critical industries (Title III), and conduct investment security review (Title VII, precursor to CFIUS). Reauthorized approximately 50 times, most recently extended through September 2025 by Pub. L. 115-263 (2018) and further extended under NDAA FY2026; it has been invoked by every Administration since 1950 and has accelerated dramatically since 2020 to target critical-minerals processing, semiconductor manufacturing, battery supply chains, biopharmaceuticals, and energy infrastructure.